/https://tf-cmsv2-smithsonianmag-media.s3.amazonaws.com/filer_public/a6/73/a673143a-c068-4f51-a040-6d4f37d601c0/gettyimages-1124673966_web.jpg?#)
Clinically relevant clot resolution via a thromboinflammation-on-a-chip
Nature, Published online: 02 April 2025; doi:10.1038/s41586-025-08804-7In thromboinflammation, early tissue plasminogen activator administration directly improves endothelial barrier function, prophylactic defibrotide and enoxaparin suppress microvascular thromboinflammation through endothelium-mediated mechanisms and combining enoxaparin with crizanlizumab reduces microvascular occlusion and protects endothelial function in sickle cell disease.
Nature, Published online: 02 April 2025; doi:10.1038/s41586-025-08804-7In thromboinflammation, early tissue plasminogen activator administration directly improves endothelial barrier function, prophylactic defibrotide and enoxaparin suppress microvascular thromboinflammation through endothelium-mediated mechanisms and combining enoxaparin with crizanlizumab reduces microvascular occlusion and protects endothelial function in sickle cell disease.
